{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:21:33Z","timestamp":1789690893557,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-RHUS-0003"],"award-info":[{"award-number":["ANR-17-RHUS-0003"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC2021\/105-01"],"award-info":[{"award-number":["RC2021\/105-01"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jhep.2022.07.016","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T19:46:58Z","timestamp":1660420018000},"page":"1525-1531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4669","authenticated-orcid":false,"given":"Elisabetta","family":"Degasperi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-5575","authenticated-orcid":false,"given":"Maria Paola","family":"Anolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2027-8478","authenticated-orcid":false,"given":"Sara Colonia","family":"Uceda Renteria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Sambarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-1256","authenticated-orcid":false,"given":"Riccardo","family":"Perbellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-8480","authenticated-orcid":false,"given":"Caroline","family":"Scholtes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-4744","authenticated-orcid":false,"given":"Floriana","family":"Facchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8022-8803","authenticated-orcid":false,"given":"Alessandro","family":"Loglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-850X","authenticated-orcid":false,"given":"Sara","family":"Monico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1328","authenticated-orcid":false,"given":"Mirella","family":"Fraquelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-6051","authenticated-orcid":false,"given":"Andrea","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-5354","authenticated-orcid":false,"given":"Ferruccio","family":"Ceriotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.07.016_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of Hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis Delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.016_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatits D","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib5","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.016_bib6","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","volume":"74","author":"Lok","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.016_bib7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis Delta: the need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib9","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30651-6","article-title":"48 weeks of high dose (10 mg) Bulevirtide as monotherapy or with Peginterferon alfa-2a in patients with chronic HBV\/HDV coinfection","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib10","first-page":"S291","article-title":"Safety and efficacy of Bulevirtide monotherapy and in combination with Peginterferon alfa-2a in patients with chronic Hepatitis Delta: 24-week interim data of MYR204 Phase 2b study","volume":"75","author":"Asselah","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib11","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(22)00433-0","article-title":"Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study","volume":"77","author":"Wedemeyer","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib12","first-page":"S148A","article-title":"Strong intrahepatic decline of Hepatitis D virus RNA and antigen after 48 weeks of treatment with bulevirtide in chronic HBV\/HDV co-infected patients: interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301)","volume":"74","author":"Allweiss","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.016_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2019.07.003","article-title":"Excellent safety and effectiveness of high-dose Myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: a case report of 3 patients","volume":"71","author":"Loglio","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib14","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with Hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.07.016_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib16","doi-asserted-by":"crossref","first-page":"S840","DOI":"10.1016\/S0168-8278(22)01975-4","article-title":"Treatment with Bulevirtide in patients with chronic HBV\/HDV coinfection. Safety and efficacy at month 18 in real-world settings","volume":"77","author":"De L\u00e9dinghen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \"real world\" study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.07.016_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","article-title":"Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis","volume":"144","author":"Berzigotti","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.016_bib19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients","volume":"39","author":"D\u2019Amico","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.07.016_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cld.2021.01.005","article-title":"Noninvasive detection of clinically significant portal hypertension in compensated advanced chronic liver disease","volume":"25","author":"Vuille-Lessard","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2022.07.016_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib24","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.016_bib25","first-page":"S447A","article-title":"Performance of a novel automated assay for the detection and quantification of HBV pregenomic RNA\/circulating RNAs in chronic HBV patients","volume":"72","author":"Scholt\u00e8s","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.016_bib26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/hep.22109","article-title":"Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease","volume":"47","author":"Kim","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.016_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17474124.2020.1815530","article-title":"Biomarkers for Hepatitis B virus replication: an overview and a look to the future","volume":"14","author":"Li","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum Hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic Hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.016_bib29","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and Hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic Hepatitis B in North America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.016_bib30","first-page":"S1408","article-title":"Cross-sectional study of serum HBV RNA and HBcrAg in a real-life prospective cohort of 1500 chronic Hepatitis B patients followed in France and Italy","volume":"74","author":"Zoulim","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.016_bib31","first-page":"S419A","article-title":"Divergent patterns of HDV-RNA and HBcrAg levels in chronic hepatitis Delta untreated patients: a large European cross-sectional study","volume":"74","author":"Loglio","year":"2021","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:31Z","timestamp":1759175251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822029804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0168827822029804"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.016","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}